Chloroquine: An Old to be Repurposed Drug For COVID-19 Infection (Risk and Benefit)
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman and 1 more
Pharmaceutical Sciences and Research · 2020
doi:10.7454/psr.v7i4.1076 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19) with a high rate of mortality. Chloroquine and hydroxychloroquine have been used for antimalarial and autoimmune diseases for many years. Due to low toxicity and well tolerability as well as immunomodulatory properties, these drugs are proposed to treat viral infection. Some studies, both in vitro and in a clinical setting, have been evaluated for their ability to treat SARS-CoV-2 as promising therapies. Although The National Agency of Drugs and Food Control of The Republic of Indonesia issued emergency authorization for chloroquine and hydroxychloroquine to be used against COVID-19 infection, the efficacy of these drugs is still based on small clinical non-randomized trials with a limited number of patients. However, the use of these drugs without any risks. The safety of these drugs to be used in COVID-19 patients is lacking. Some experts noticed that the drugs cause harmful adverse effects, especially a harmful QT prolongation. In Indonesia, until now, no study evaluates the effectiveness as well as the safety of these drugs to be used in COVID-19 infection. In conclusion, their use can still be considered by assessing the benefits and risks to patients. This article will discuss the role of chloroquine or hydroxychloroquine and its safety to be used against COVID-19 infection.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.